BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen
The second blank-check vehicle from Cormorant's Bihua Chen plans to take BridgeBio's oncology spinout onto the Nasdaq. The special purpose acquisition company — known as Helix Acquisition Corp. II — will combine with BridgeBio Oncology Therapeutics, the ...
The second blank-check vehicle from Cormorant's Bihua Chen plans to take BridgeBio's oncology spinout onto the Nasdaq.
The special purpose acquisition company — known as Helix Acquisition Corp. II — will combine with BridgeBio Oncology Therapeutics, the ...
